TYK2: tyrosine kinase 2
1 protein, 45 patents, 18 drugs, 774 trials, 3,831 NIH grants and 7,661 papers.
Gene 7
Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.
Proteins 1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in | Source |
|---|---|---|---|---|---|
| P29597 | Non-receptor tyrosine-protein kinase TYK2 | 1,187 | 52 | Ensembl, GeneID, HGNC | UniProt |
Patents 45
Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 12539325 B2 | 2026-02-03 | 56 | P29597 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 68804 | P29597 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 68805 | P29597 | Espacenet |
| EP 4640849 A2 | 2025-10-29 | 290 | P29597 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 1982 | P29597 | Espacenet |
| JP 2025519096 A | 2025-06-24 | 290 | P29597 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 1982 | P29597 | Espacenet |
| US 12133879 B2 | 2024-11-05 | 56 | P29597 | Espacenet |
| US 11957931 B2 | 2024-04-16 | 4 | P29597 | Espacenet |
| US 11884978 B2 | 2024-01-30 | 786 | P29597 | Espacenet |
Drugs 18
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BREPOCITINIB | CHEMBL4297477 | Tyrosine-protein kinase TYK2 inhibitor | INHIBITOR | ChEMBL |
| CERDULATINIB | CHEMBL4116008 | Tyrosine-protein kinase TYK2 inhibitor | INHIBITOR | ChEMBL |
| CRAVACITINIB | CHEMBL4596392 | Tyrosine-protein kinase TYK2 negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | ChEMBL |
| DELGOCITINIB | CHEMBL4297507 | Janus Kinase (JAK) inhibitor | INHIBITOR | ChEMBL |
| DEUCRAVACITINIB | CHEMBL4435170 | Tyrosine-protein kinase TYK2 negative allosteric modulator | NEGATIVE ALLOSTERIC MODULATOR | ChEMBL |
| DEURUXOLITINIB PHOSPHATE | CHEMBL4594382 | Tyrosine-protein kinase TYK2 inhibitor | INHIBITOR | ChEMBL |
| FILGOTINIB | CHEMBL3301607 | Tyrosine-protein kinase TYK2 inhibitor | INHIBITOR | ChEMBL |
| FILGOTINIB MALEATE | CHEMBL4298167 | Tyrosine-protein kinase TYK2 inhibitor | INHIBITOR | ChEMBL |
| GUSACITINIB | CHEMBL4594275 | Janus Kinase (JAK) inhibitor | INHIBITOR | ChEMBL |
| IZENCITINIB | CHEMBL4650343 | Janus Kinase (JAK) inhibitor | INHIBITOR | ChEMBL |
Trials 774
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07598643 | TOFACITINIB | PHASE2 | ClinicalTrials.gov | |
| NCT07597577 | UPADACITINIB | ClinicalTrials.gov | ||
| NCT07595939 | RUXOLITINIB | PHASE3 | ClinicalTrials.gov | |
| NCT07588568 | UPADACITINIB | PHASE2 | ClinicalTrials.gov | |
| NCT07581418 | TOFACITINIB | ClinicalTrials.gov | ||
| NCT07576010 | RUXOLITINIB | PHASE1 | ClinicalTrials.gov | |
| NCT07566897 | RUXOLITINIB | PHASE1 | ClinicalTrials.gov | |
| NCT07564271 | DEUCRAVACITINIB | ClinicalTrials.gov | ||
| NCT07554820 | TOFACITINIB | PHASE4 | ClinicalTrials.gov | |
| NCT07554495 | FILGOTINIB | PHASE3 | ClinicalTrials.gov |
NIH grants 3831
NIH projects whose papers are about the gene, through NIH's grant-paper links.
| Project | Title | Its papers about the gene | Newest fiscal year | Source |
|---|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 41 | 2,025 | NIH's project files |
| UL1TR001866 | Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational Success | 40 | 2,025 | NIH's project files |
| P30CA008748 | Cancer Center Support Grant | 34 | 2,025 | NIH's project files |
| ZIAAR041159 | Cytokine Signaling, Immunoregulation and Autoimmune and Immunodeficiency Diseases | 26 | 2,025 | NIH's project files |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 23 | 2,025 | NIH's project files |
| UL1TR001863 | Yale Clinical and Translational Science Award | 21 | 2,025 | NIH's project files |
| P30CA016058 | Cancer Center Support Grant | 20 | 2,025 | NIH's project files |
| ZICAR041181 | Translational Immunology research: a support for clinical immunological research | 18 | 2,025 | NIH's project files |
| R01AI127564 | Genome-wide search for inborn errors of IL-17 immunity underlying chronic mucocutaneous candidiasis | 16 | 2,025 | NIH's project files |
| ZIAAI000646 | Transgenic Animal Models Of Human Immune Defects | 14 | 2,025 | NIH's project files |
Papers 7661
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| PMID | Found by | Source |
|---|---|---|
| 42825998 | PubTator, text mining | PubMed |
| 42818629 | PubTator, text mining | PubMed |
| 42804788 | PubTator, text mining | PubMed |
| 42786248 | PubTator, text mining | PubMed |
| 42786200 | PubTator, text mining | PubMed |
| 42779165 | PubTator, text mining | PubMed |
| 42769975 | PubTator, text mining | PubMed |
| 42769501 | PubTator, text mining | PubMed |
| 42762643 | PubTator, text mining | PubMed |
| 42761984 | PubTator, text mining | PubMed |
Release gene-search-2026-11-11-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
HGNC: CC0: https://www.genenames.org/about/license/
NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH's project files and grant-paper links: Public domain (NIH RePORTER)
Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubTator 3: Public domain
UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license